Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor class drugs

9 results

  • apretude

    (Cabotegravir)
    ViiV Healthcare Company
    APRETUDE is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk of HIV-1. A negative HIV-1 test is required before starting treatment.

  • cabenuva

    (cabotegravir and rilpivirine)
    ViiV Healthcare Company
    CABENUVA is indicated as a complete regimen for treating HIV-1 infection in adults and adolescents aged 12 and older (weighing at least 35 kg) who are virologically suppressed and stable on their current antiretroviral therapy, with no treatment failure history or known resistance to its components.

  • dovato

    (dolutegravir sodium and lamivudine)
    ViiV Healthcare Company
    DOVATO is indicated for the treatment of HIV-1 infection in adults and adolescents (12 years and older, weighing at least 25 kg) who are either treatment-naive or virologically suppressed on a stable regimen without known resistance issues.

  • genvoya

    (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
    Gilead Sciences, Inc.
    GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥25 kg) with no prior antiretroviral treatment history or to replace an existing regimen in virologically-suppressed patients on a stable regimen for at least six months without treatment failures or resistance.

  • isentress

    (RALTEGRAVIR)
    Merck Sharp & Dohme LLC
    ISENTRESS® and ISENTRESS® HD are indicated for the treatment of HIV-1 infection in adults and pediatric patients, used in combination with other antiretroviral agents. ISENTRESS is for children weighing at least 2 kg, while ISENTRESS HD is for those weighing at least 40 kg.

  • juluca

    (dolutegravir sodium and rilpivirine hydrochloride)
    ViiV Healthcare Company
    JULUCA is indicated for treating HIV-1 infection in virologically suppressed adults, replacing their current antiretroviral regimen. Eligible patients must have maintained suppression for at least 6 months, have no treatment failures, and no known resistance to JULUCA's components.

  • stribild

    (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    STRIBILD® is indicated for treating HIV-1 in adults and pediatric patients aged 12 and older (weighing at least 35 kg) without prior antiretroviral treatment or to replace a stable regimen in those virologically suppressed for at least 6 months, without resistance to its components.

  • tivicay pd

    (dolutegravir sodium)
    ViiV Healthcare Company
    TIVICAY and TIVICAY PD are indicated for treating HIV-1 infection in adults and pediatric patients (aged 4 weeks and older, weighing at least 3 kg) in combination with other antiretrovirals. TIVICAY can also replace a stable regimen in adults who are virologically suppressed.

  • triumeq

    (abacavir sulfate, dolutegravir sodium, lamivudine)
    ViiV Healthcare Company
    TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and pediatric patients aged at least 3 months and weighing at least 6 kg. They are not recommended for patients with integrase resistance or suspected INSTI resistance due to insufficient dolutegravir dosage.